​Head & Neck

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

• (108-19) ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

• (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

• (157-17) FID-007 in Treating Participants With Advanced Solid Tumors

• (161-19) PET MRI as a Staging Tool for Head and Neck Cancer (Clinical research study, appropriate for patients with head and neck cancer.)

• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
• (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

• (189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

• (201-19) A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40 Antibody in Subjects with Advanced Solid Tumors

• (205-19) Study to Assess AFM24 in Advanced Solid Cancers

• (207-20) An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

• (214-17) An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.